All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
AstraZeneca reports 6% rise in Q2 2024 net profit to $1.92bn
The British pharmaceutical company reported total revenues of $12.93bn for Q2 2024, a 13% increase compared to $11.41bn for the same quarter in 2023, and a 2% rise compared to $12.67bn for Q1 2024
BioMarin gets expanded FDA approval for Brineura to treat CLN2 Disease in children
Brineura is a recombinant form of human tripeptidyl peptidase 1 (TPP1), the enzyme which is deficient in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as the Jansky–Bielschowsky disease
Danaher reports 18% decline in Q2 2024 net income to $907m
The life sciences company reported net sales of $5.74bn for Q2 2024, a 2.8% decline compared to $5.91bn for the same quarter in the previous year, and a 1% decrease compared to $5.79bn for Q1 2024.
Agilent to acquire Canadian CDMO Biovectra for $925m
Biovectra manufactures biologics, pharmaceutical ingredients, and other molecules for targeted therapeutics, from early-stage clinical development to large-scale commercial manufacturing, for biotech and pharmaceutical companies
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks
MHRA approves Lupin-Zentiva’s generic HIV drug Isentress
Isentress works to reduce the function of HIV integrase and may reduce the amount of HIV in the patient’s blood and increase the patient’s levels of CD4 cells, a type of white blood cells that play a key role in maintaining a healthy immune system
SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases
Phathom secures FDA approval for Voquezna to treat non-erosive GERD
The FDA approval of Voquezna in non-erosive GERD is supported by the positive results from the Phase 3 PHALCON-NERD-301 study, which evaluated Voquezna’s efficacy and safety in non-erosive GERD
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
New intellectual property significantly broadens potential patient population for lasofoxifene, which previously demonstrated antitumor activity in breast cancers with ESR1 mutations
Marinus gets China’s NMPA approval for Ztalmy to treat seizures
Ztalmy is a neuroactive steroid GABAA receptor modulator that targets a brain receptor known for its anti-seizure properties and is already approved in the US and European Union (EU) for treating CDD-associated epileptic seizures